Entrada Therapeutics, Inc. (TRDA)
Automate Your Wheel Strategy on TRDA
With Tiblio's Option Bot, you can configure your own wheel strategy including TRDA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TRDA
- Rev/Share 1.9225
- Book/Share 9.1803
- PB 0.5468
- Debt/Equity 0.1442
- CurrentRatio 18.6409
- ROIC -0.2111
- MktCap 190946142.0
- FreeCF/Share -3.0615
- PFCF -1.5087
- PE -2.8291
- Debt/Assets 0.122
- DivYield 0
- ROE -0.1781
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TRDA | ROTH MKM | -- | Buy | -- | $29 | Dec. 6, 2024 |
News
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to earnings of $1.55 per share a year ago.
Read More
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Entrada Therapeutics (TRDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors.
Read More
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to earnings of $0.68 per share a year ago.
Read More
Entrada Therapeutics Reports First Quarter 2025 Financial Results
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping – – Company remains on track to initiate ELEVATE-44-201 and ELEVATE-45-201 in Q2 and Q3 2025, respectively – – Cash runway expected into Q2 2027 with $383 million in cash, cash equivalents and marketable securities as of March 31, 2025 – BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial results for the first quarter ended March 31, 2025, and highlighted recent business …
Read More
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Company on track to initiate ELEVATE-45-201 study in Q3 2025 – – ELEVATE-45 regulatory filings submitted in the EU, with regulatory review ongoing – – ELEVATE-45 is the second of three novel exon skipping Duchenne programs the Company expects to progress into global clinical development in 2025 – BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced it has received authorization from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee to initiate ELEVATE-45-201. ELEVATE-45-201 is a Phase 1/2 multiple ascending dose (MAD) clinical study to evaluate Entrada's investigational …
Read More
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Received FDA authorization to initiate ELEVATE-44-102 in the U.S. – – Received MHRA authorization to initiate ELEVATE-44-201 in the U.K. – – Submitted regulatory filings to support global clinical studies for ENTR-601-44 in the EU, and ENTR-601-45 in the U.K. and EU – – Cash runway expected into Q2 2027 with $420 million in cash, cash equivalents and marketable securities as of December 31, 2024 – BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial results for the fourth quarter and full year ended December 31, 2024 and highlighted recent business updates. “We …
Read More
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-44-201 – – Expands global ELEVATE-44 clinical program to include pediatric, adult, ambulatory and non-ambulatory patients with Duchenne muscular dystrophy – BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the United States Food and Drug Administration (FDA) has lifted the clinical hold on ENTR-601-44 and provided authorization to initiate ELEVATE-44-102, a Phase …
Read More
Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Entrada Therapeutics addresses intracellular drug delivery challenges with its Endosomal Escape Vehicle platform, positioning itself uniquely in the biotech sector. Strong financials with $449.3 million in reserves and strategic partnerships extend Entrada's runway into 2027, reducing near-term financing risks. ENTR-601-44, targeting Duchenne muscular dystrophy, is entering critical trials, with potential to validate the platform and drive significant market share.
Read More
About Entrada Therapeutics, Inc. (TRDA)
- IPO Date 2021-10-29
- Website https://www.entradatx.com
- Industry Biotechnology
- CEO Dipal Doshi
- Employees 183